Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-07
2006-02-07
Richter, Johann (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S527000, C546S247000, C558S390000
Reexamination Certificate
active
06995180
ABSTRACT:
A compound of the formula I:wherein R1, R2, R3and R4are as defined herein.Further provided are methods of using such compounds for the treatment of diabetes and related diseases, and to pharmaceutical compositions containing such compounds.
REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 3983140 (1976-09-01), Endo et al.
patent: 4027009 (1977-05-01), Grier et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4448784 (1984-05-01), Glamkowski et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4499289 (1985-02-01), Baran et al.
patent: 4613610 (1986-09-01), Wareing
patent: 4647576 (1987-03-01), Hoefle et al.
patent: 4681893 (1987-07-01), Roth
patent: 4686237 (1987-08-01), Anderson
patent: 4759923 (1988-07-01), Buntin et al.
patent: 4871721 (1989-10-01), Biller
patent: 4924024 (1990-05-01), Biller
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5273995 (1993-12-01), Roth
patent: 5346701 (1994-09-01), Heiber et al.
patent: 5354772 (1994-10-01), Kathawala
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5506219 (1996-04-01), Robl
patent: 5541204 (1996-07-01), Sher et al.
patent: 5594016 (1997-01-01), Ueno et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5614492 (1997-03-01), Habener
patent: 5631224 (1997-05-01), Efendic et al.
patent: 5686104 (1997-11-01), Mills et al.
patent: 5691322 (1997-11-01), Robl
patent: 5712279 (1998-01-01), Biller et al.
patent: 5712396 (1998-01-01), Magnin et al.
patent: 5739135 (1998-04-01), Biller et al.
patent: 5753675 (1998-05-01), Wattanasin
patent: 5760246 (1998-06-01), Biller et al.
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5827875 (1998-10-01), Dickson, Jr. et al.
patent: 5885983 (1999-03-01), Biller et al.
patent: 5962440 (1999-10-01), Sulsky
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 0 142 146 (1985-05-01), None
patent: 0 221 025 (1987-05-01), None
patent: 2 596 393 (1987-10-01), None
patent: 2 205 837 (1988-12-01), None
patent: WO 86/03488 (1986-06-01), None
patent: WO 86/07054 (1986-12-01), None
patent: WO 96/38144 (1996-12-01), None
patent: WO 97/12613 (1997-04-01), None
patent: WO 97/12615 (1997-04-01), None
patent: WO 97/21993 (1997-06-01), None
patent: WO 99/00353 (1999-01-01), None
patent: WO 99/38501 (1999-08-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/67278 (1999-12-01), None
patent: WO 99/67279 (1999-12-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO2004/037181 (2004-05-01), None
Ashworth, D.M. et al., “2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Bioorganic & Medicinial Chemistry Letters, vol. 6, No. 10, pp. 1163-1166 (1996).
Ashworth, D.M. et al., “4-Cyanothiazolidides as Very Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Bioorganic & Medicinial Chemistry Letters, vol. 6, No. 22, pp. 2745-2748 (1996).
Biller, S.A. et al., “Isoprenoid (Phosphinylmethyl)phosphonates as Inhibitors of Squalene Synthetase”, Journal of Medicinal Chemistry, vol. 31, No. 10, pp. 1869-1871 (1988).
Biller, S.A. et al., “Squalene Synthase Inhibitors”, Current Pharmaceutical Design, vol. 2, pp. 1-40 (1996).
Bundgaard, H., Chapter 5: “Design and Application of Prodrugs”, A Textbook of Drug Design and Development, Harwood Academic Publishers, publ., Krogsgaard-Larsen, P. and Bundgaard, T., eds., pp. 113-191 (1991).
Bundgaard, H., ed., Design of Prodrugs, Elsevier Science Publishers B.V., publ. (1985) (table of contents).
Capson, T.L., “Synthesis and Evaluation of Ammonium Analogs of Carbocationic Intermediates in Squalene Biosynthesis”, dissertation, Department of Medicinal Chemistry, University of Utah, pp. iv-v, Table of Contents, 16-17, 40-43, 48-51, Summary (Jun. 1987).
Corey, E.J. et al., “Application of Unreactive Analogs of Terpenoid Pyrophosphates to Studies of Multistep Biosynthesis. Demonstration That ‘Presqualene Pyrophosphate’ Is an Essential Intermediate on the Path to Squalene”, J. Am. Chem. Soc., vol. 98, No. 5, pp. 1291-1293 (1976).
Cornicelli, J.A. et al., “15-Lipoxygenase and Its Inhibition: A Novel Therapeutic Target for Vascular Disease”, Current Pharmaceutical Design, vol. 5, pp. 11-20 (1999).
Ghiselli, G., “The Pharmacological Profile of FCE 27677: A Novel ACAT Inhibitor with Potent Hypolipidemic Activity Mediated by Selective Suppression of the Hepatic Secretion of ApoB-100-Containing Lipoprotein”, Cardiovascular Drug Reviews, vol. 16, No. 1, pp. 16-30 (1998).
Hanessian, S. et al., “Probing the Importance of Spacial and Conformational Domains in Captopril Analogs for Angiotensin Converting Enzyme Activity”, Bioorganic & Medicinal Chemistry Letters, vol. 8, pp. 2123-2128 (1998).
Hara, S., “Ileal Na+/bile acid cotransporter inhibitors”, Drugs of the Future, vol. 24, No. 4, pp. 425-430 (1999).
Hughes, T.E. et al., “(1-[[[2-[(5-Cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine), a Slow-Binding Inhibitor of Dipeptidyl Peptidase IV”, Biochemistry, vol. 38, pp. 11597-11603 (1999).
Johannsson, G. et al., “Growth Hormone Treatment of Abdominally Obese Men Reduces Abdominal Fat Mass, Improves Glucose and Lipoprotein Metabolism, and Reduces Diastolic Blood Pressure”, Journal of Clinial Endocrinology and Metabolism, vol. 82, No. 3, pp. 727-734 (1997).
Krause, B.R. et al., Chapter 6: “ACAT Inhibitors: Physiologic Mechanisms for Hypolipidemic and Anti-Atherosclerotic Activities in Experimental Animals”, Inflammation: Mediators Pathways, CRC Press, Inc., publ., Ruffolo, Jr., R.R. and Hollinger, M.A., eds., pp. 173-198 (1995).
McClard, R.W. et al., “Novel Phosphonylphosphinyl (P-C-P-C-) Analogues of Biochemically Interesting Diphosphates. Syntheses and Properties of P-C-P-C- Analogues of Isopentenyl Diphosphate and Dimethylallyl Diphospate and Dimethylally Diphosphate”, J. Am. Chem. Soc:, vol. 109, pp. 5544-5545 (1987).
Murakami, K. et al., “A Novel Insulin Sensitizer Acts as a Coligand for Peroxisome Proliferator-Activated Receptor-α (PPAR-α) and PPAR-γ—Effect of PPAR-α Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats”, Diabetes, vol. 47, pp. 1841-1847 (1998).
Nagatsu, T. et al., “New Chromogenic Substrates for X-Prolyl Dipeptidyl-Aminopeptidase”, Analytical Biochemistry, vol. 74, pp. 466-476 (1976).
Nicolosi, R.J. et al., “The ACAT Inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters”, Atherosclerosis, vol. 137, pp. 77-85 (1998).
Oritz de Montellano, P.R. et al., “Inhibition of Squalene Synthetase by Farnesyl Pyrophosphate Analogues”, Journal of Medicinal Chemistry, vol. 20, No. 2, pp. 243-249 (1977).
Rahfeld, J. et al., “Extended Investigation of the Substrate Specificity of Dipeptidyl Peptidase IV from Pig Kidney”, Biol. Chem. Hoppe-Seyler, vol. 372, pp. 313-318 (1991).
Rosenblum, S.B. et al., “Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption”, J. Med. Chem., vol. 41, pp. 973-980 (1998).
Sagnard, I. et al., “Enantioselective Synthesis of Cyclopropane α-Amino Acids: Synthesis of N-Boc-cis-(2S,3R,4S)-3,4-Methanoproline and N-Boc-(2S,3R,4S)-3,4,-Methanoglutamic Acid”, Tetrahedron Letters, vol. 36, No. 18, pp. 3149-3152 (1995).
Salisbury, B.G. et al., “Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption,
Hamann Lawrence G.
Magnin David R.
Bristol Myers Squibb Company
O'Brien Maureen P.
Provoost Jonathan N.
Richter Johann
Sackey Ebenezer
LandOfFree
Glycinenitrile-based inhibitors of dipeptidyl peptidase IV... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glycinenitrile-based inhibitors of dipeptidyl peptidase IV..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycinenitrile-based inhibitors of dipeptidyl peptidase IV... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3672023